Readers discuss an essay about whether it is a disease and how it should be diagnosed. Also: Fear in schools; natural ...

In this detailed exploration, we will delve into a comparative analysis of two such supplements that have been gathering ...

The FDA cleared Eversense 365 as the first 1-year integrated continuous glucose monitoring (CGM) system for adults with type ...

The trial investigated the efficacy and safety of a once-daily 10-mg, 20-mg, and 50-mg dose of monlunabant vs. placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome.

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

Many of us are searching for effective ways to boost our metabolism and burn fat more efficiently. That's where fat burners ...

Finding free dietitian CEUs is not an easy task, so we did the job for... The post Free Dietitian CEUs appeared first on For ...

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

With a growing portfolio in an attractive rare-disease niche—and acceleration of profit growth beginning in 2022—BioMarin could be an acquisition target for pharmaceutical firms with pipelines to fill ...

These five top stocks trade at reasonable levels and offer the strength that makes sense as we enter a very volatile time of ...